



Notch signalling is a conserved developmental pathway involved, inter alia, in cell-fate decision, 
morphogenesis and tissue patterning. Extensive research has linked this pathway with a variety of 
malignancies, cancer stem cell renewal, induction of epithelial-to-mesenchymal transition and 
tumour angiogenesis. These data indicate that Notch can act as both a tumour suppressor and an 
oncoprotein, depending upon cellular context and identify it as a potential therapeutic target in 
cancer treatment. This review discusses the implications of Notch in a number of hematologic and 
solid malignancies and some of the currently available inhibitors developed against this pathway as 
potential cancer therapeutics. 
 







Notch signalling is an evolutionary conserved pathway present in most multicellular organisms. It 
was first described by Dexter1 who observed the appearance of a notch in the wings of Drosophila 
melanogaster. This feature became the namesake of the ‘notch’ gene and was later found to be the 
consequence of an X-linked, dominant mutation that causes irregular tissue loss in the wings of the 
fruit fly. In 1917, Morgan2 identified the alleles of the gene which was later analysed and sequenced 
in successive years by two different groups3, 4. 
 
Physiological roles of Notch signalling 
The Notch pathway regulates a variety of cell fate decisions and cellular processes in invertebrate 
and vertebrate embryonic development and continues to remain involved in adult tissue 
homeostasis5. During embryonic development, Notch is involved in four main processes; (1) lateral 
inhibition which determines cell fates and spatial patterning (for example, segregation of neural and 
epidermal lineages or selection of a sensory organ precursor during neurogenesis)6, (2) asymmetric 
cell fate division as a mechanism to generate cell diversity and differentiate cells prior to mitosis 
through cell polarity regulation, (3) boundary formation – e.g. boundary establishment between 
prospective somites during somitogenesis or the formation of dorsal and ventral margins in the 
wing imaginal disc, (4) endocrine gland development through the activities of the Notch target 
genes Hes1 and Hes57-9. Notch-mediated signals are able to control divergent programs of 
differentiation in many tissues, including muscle, skin, pancreas and the vascular, nervous and 
hematopoietic systems10. In the adult body, Notch is involved in renewal and maintenance of 
various organs such as kidneys, lungs, liver, muscle and bone11.  
 
The Molecular biology of Notch signalling 
Notch receptors – structure and maturation 
Notch (Fig.1) is a 300 kDa single-pass, transmembrane protein4, 7, 12 that can act as both a receptor 
and a transcription factor. While Drosophila has only one Notch receptor, mammals express four 
(Notch1-4). The extracellular domains of Notch1 and Notch2 contain a tandem array of 36 
epidermal growth factor (EGF)-like repeats, while Notch3 and Notch4 have 34 and 29 repeats, 
respectively4, 13. Only two of these EGF-like repeats, 11 and 12, are necessary for receptor-ligand 
interaction. The EGF-like repeats are followed by three cysteine-rich, LIN Notch repeats (LNRs)14.  
The Notch intracellular domain is also structurally complex and consists of a RBP-Jκ/CBF1 
association module (RAM) domain, six ankyrin repeats, a proline, serine, glutamic acid and 
threonine-rich (PEST) domain and, finally, a transactivation domain (TAD) which is absent from 
Notch3 and Notch413-16. 
The Notch receptor is proteolytically cleaved at the S1 site (between the EGF-like and LNR 
repeats) whilst in the Golgi apparatus15 by a furin–like convertase (Fig.2). This event yields two 
fragments that are held together non-covalently through a juxtamembrane heterodimerisation 
domain (HD)17. Also in the Golgi apparatus, Notch is subject to glycosylation, performed by O-
fucosyltransferase and Fringe12, 13, 15, 18, 19. Vertebrates have three Fringe homologues; Radical, 
Manic and Lunatic8. 
Canonical and non-canonical Notch signalling 
The mature Notch heterodimers are held in an auto-inhibited state by a juxtamembrane negative 













Figure 1. The modular domain structure of mammalian Notch receptors.  
The extracellular domain of all Notch receptors contains multiple epidermal growth factor (EGF)-
like repeats and three LIN Notch repeats (LNR) followed by the heterodimerization domain (HD). 
The cytosolic domain consists of a RBP-Jκ/CBF1 association module (RAM) domain and several 
ankyrin repeats (ANK). In addition, Notch receptors 1-3 contain a Notch cytokine response (NCR) 
region and Notch 1 and 2 contain a transactivation domain (TAD). Finally, all four receptors 












Figure 2. Trafficking and proteolysis of Notch.  
The Notch receptor is proteolytically cleaved at the S1 site in the Golgi apparatus by a furin–like 
convertase. At the cell surface, Notch undergoes S2 cleavage by members of the ADAM family. 
The residual C-terminal fragment then undergoes S3/4 cleavage by the -secretase complex yielding 
the Notch intracellular domain (NICD) which translocates to the nucleus where it can modulate 
transcriptional events through its displacement of co-repressors associated with CSL. Mastermind-
like (MAML) protein is then recruited to form a ternary complex. Possible therapeutic intervention 
points are shown in red.  
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protein20, 21. This prevents activation of the Notch pathway by physically blocking the S2 cleavage 
site until a suitable ligand binds to the Notch receptor20. Upon ligand binding, the receptor 
undergoes a conformational change exposing the S2 site allowing proteolytic cleavage (Fig.2)8, 20. 
Cleavage occurs at the S2 site, between Ala-1710 and Val-1711, and is mediated by a disintegrin 
and metalloproteinase (ADAM) 17 also known as tumour necrosis factor alpha (TNFα)-converting 
enzyme (TACE)22, 23. 
Proteolysis of Notch by TACE is followed by cleavage at the S3 site (Fig. 2) mediated by γ-
secretase, a multiprotein complex consisting of Pen2, nicastrin, Aph-1 and presenilin, with the 
aspartyl proteinase catalytic site located in the presenilin protein8, 23-25. Nicastrin promotes the 
maturation and proper trafficking of other proteins in the complex26, 27. S3 cleavage leads to the 
cytoplasmic release of Notch intracellular domain (NICD) (Fig.2) which then translocates to the 
nucleus28. 
Once in the nucleus (Fig.2), the NICD can modulate transcriptional events through its interaction 
with the DNA-binding factor CSL (CBF1, Suppressor of Hairless, Lag-1) that acts as both a 
transcriptional repressor and activator29. NICD displaces the co-repressors associated with CSL and 
together they recruit co-activators from the Mastermind-like (MAML) protein family to form a 
ternary complex8, 30, 31. Formation of the ternary complex depends on the ankyrin repeats of the 
Notch receptor31, 32.   Table 1 provides a list of some of the more extensively studied target genes 
regulated in this manner. 
 
Table 1: Known Notch target genes and their roles (adapted33, 34). 
Target gene Role/Function 
Hes1, Hes5, Hes7 encode nuclear proteins that suppress transcription35 
Hey1, Hey2, HeyL encode nuclear proteins that suppress transcription36 
Nanog embryonic stem cell marker34 
CD25 interleukin-2 receptor, pre-T cell receptor α chain33 
cyclin D1 encodes a protein involved in regulating cell cycle progression37 
CDK2 encodes a protein involved in regulating cell cycle progression37 
DTX1 encodes Deltex-1, a E3 ubiquitin ligase38 
c-Myc proto-oncogene involved in growth control, differentiation and 
apoptosis39 
p21WAF1 cyclin-dependent kinase inhibitor, regulates cell cycle 
progression40 
NFκB encodes a protein complex that controls a large number of cellular 
processes41   
Ifi-202, Ifi-204, Ifi-D3 encode interferon-inducible proteins42 
ADAM19 a disintegrin and metalloprotease; cleaves cell surface proteins43 
Bcl-2 apoptosis regulator44 
HoxA5, HoxA9, HoxA10 regulators of animal development45 
Slug transcriptional repressor46 
Survivin apoptosis regulator47 
NRARP Notch negative regulator48 





Protein degradation is seen as an effective means of regulating the Notch signalling pathway as it 
keeps the levels of the NICD just above a functional threshold8. The stability of the NICD is 
regulated by several E3 ubiquitin ligases (Deltex, Itch/AIP4, NEDD4, FBXW7 and Cbl) and 
polyubiquitination targets the fragment for either lysosomal degradation or recycling to the plasma 
membrane, both via endocytosis50, 51. Numb, a cytoplasmic negative regulator of Notch that acts 
upstream of the γ-secretase complex, and AP2 are also able to promote Notch degradation (Fig.2)50, 
52, 53. 
While canonical Notch signalling is able to mediate a number of biological processes, a non-
canonical function of Notch has also been reported through the activity of ligands such as 
F3/contactin, DLK1-2, DNER and EGFL7. Non-canonical Notch is able to activate transcription 
independently of CSL. For instance, Notch can post-translationally target Wnt/β-catenin 
signalling54 or promote the maturation of CD4+ and CD8+  without formation of a ternary 
complex50. 
Notch ligands – structure and proteolysis 
Canonical Notch ligands are type I transmembrane proteins, part of the DSL (Delta/Serrate/Lag2) 
family and only affect the activity of adjacent cells expressing the receptor7. The mammalian 
genome encodes five distinct ligands; Delta-like ligand (DLL) 1, 3 and 4 along with Jagged1 and 
214, 55. Although, recently, it has been suggested that DLL3 inhibits rather than activates Notch 
signalling56. The effects of certain ligands on mammalian Notch signalling may vary, depending on 
which of the four receptors is involved. 
DSL ligands share a commonly structured extracellular region which is comprised of an N-terminal 
domain followed by a DSL domain and multiple EGF-like repeats (both calcium and non-calcium 
binding), the latter of which are essential for the interaction with Notch (Fig.3)5, 57. The N-terminal 
domain consists of an N1 cysteine-rich region and an N2 cysteine-free region with a conserved 
glycosphingolipid-binding motif58. The extracellular region of the DSL ligands differs in terms of 
the number of EGF-like repeats as well as the presence of a cysteine-rich region in Serrate/Jagged 
ligands that shares partial homology with the Von Willebrand factor. In addition, some DSL ligands 









Figure 3. The modular domain structure of mammalian Notch ligands.  
The mammalian genome encodes five distinct ligands; Delta-like ligand (DLL) 1, 3 and 4 along 
with Jagged1 and 2. Each ligand contains an epidermal growth factor (EGF)-like repeat region (15-
16 repeats in Jagged ligands and 6-8 in DLLs), a DSL (Delta/Serrate/Lag2) region and N1 and N2 





Delta and Notch accumulate in endocytic vesicles and a number of recent studies have shown that 
ligand immobilisation and endocytosis of the extracellular domain of Delta is necessary for signal 
activation57, 59. Like their receptors, DSL ligands undergo O- and N-linked glycan modifications19 
and are proteolytically processed by ADAMs and γ-secretase60-63. Ligand ectodomain shedding 
produces membrane bound C-terminal fragments that compete with Notch for γ-secretase cleavage 
and lead to the loss of Notch signalling62. The DSL ligand intracellular domain contains multiple 
lysine residues that can act as sites for the attachment of ubiquitin by E3 ligases. Neutralised and 
Mindbomb are ubiquitin ligases that influence Notch signalling through their interaction with DSL 
ligands64, 65. Neutralised interacts with Delta and promotes its internalisation and degradation 
through ubiquitination; the resultant loss of Delta at the cell surface is thought to indirectly promote 
Notch signalling by relieving the cis-inhibition imposed by Delta. Mindbomb also ubiquitinates and 
upregulates Delta endocytosis but, in contrast to Neutralised, it functions exclusively in the 
activation of trans-Notch signalling. 
 
Notch signalling in cancer 
Notch is one of the key pathways in embryonic development and, as such, it is not surprising that 
irregularities in Notch signalling have been associated with various genetic physical disorders and 
cancers. Examples of genetic diseases resulting from dysfunctional Notch signalling include 
Alagille syndrome which results from mutations in Jagged1 or Notch211, 66, spondylocostal 
dysostosis linked to DLL3 mutations10, and CADASIL (cerebral autosomal dominant arteriopathy 
with subcortical infarcts and leukoencephalopathy) caused by Notch3 mutations67. 
In terms of cancer, Notch has been shown to influence carcinogenesis through its extensive cross-
talk with other signalling pathways linked to development. Notch activates the PI3kinase/Akt 
pathway which inhibits apoptosis68-70 and operates in an interdependent fashion with the 
Ras/Mitogen Activated Protein Kinase (MAPK)71, 72, NF-κB  and PPARγ pathways73, 74.  
Furthermore, Notch also interacts with and/or influences the expression of receptor tyrosine kinases 
such as fibroblast growth factor receptor (FGFR)75-77, vascular endothelial growth factor receptor 
(VEGFR)78-80 and epidermal growth factor receptor (EGFR)81, 82. Notch and the transforming 
growth factor-β (TGF-β) signalling pathways play critical roles during development83-85 and several 
interactions between Notch and the Wnt/β-catenin86-88 and Hedgehog pathways have also been 
established89, 90 
Dysregulation of the Notch pathway has been associated with a wide range of solid tumours and 
hematologic malignancies. However, depending on the tissue and organ site in which it is 
expressed, the Notch pathway can be either oncogenic or tumour suppressive (Table 2). 
 
Notch signalling in an oncogenic role 
T-cell acute lymphoblastic leukaemia 
T-cell acute lymphoblastic leukaemia (T-ALL) is an aggressive malignant disease affecting mainly 
children and adolescents. The survival rate is up to 80% but patients that relapse show a poor 
prognosis91. Notch signalling is essential for T-cell lineage commitment and oncogenic Notch 
signalling has been well documented in T-ALL51, 92. In fact, more than 50% of human T-ALL cases 




Table 2: Oncogenic and tumour suppressive roles of Notch in a variety of cancers (adapted11, 
13, 93).  
Type of cancer Function Notch/Ligand 
Acute myeloid leukaemia  Notch1-2 , DLL1 and DLL4 tumour suppressor; 
Jagged2 oncogene 
B-cell acute lymphoblastic 
leukaemia 
 Notch1-4  
B-cell chronic lymphocytic 
leukaemia 
 Notch1-2, Jagged1-2 
Chronic myelomonocytic 
leukaemia 
 Undetermined  
Chronic lymphocytic 
leukaemia 
 5-12% Notch1 mutations 
Diffuse large B-cell 
lymphoma 
 Notch2 
Hodgkin’s lymphoma  Notch1 
Mantle cell lymphoma  ~10% Notch1 mutations 
Marginal zone lymphoma  Notch2 
Multiple myeloma  Notch1-2, Jagged1-2 oncogenes; Notch1 tumour 
suppressor 
T-cell acute lymphoblastic 
leukaemia 
 Notch1-3 and DLL4 oncogenes; Notch2 tumour 
suppressor; 60% Notch1 and 30% FBXW7 
mutations 
Adenocarcinoma of the lung  Notch1, Notch3, Jagged2 
Breast cancer  Notch1-2, Notch4, Jagged1 oncogenes; Notch2 
tumour suppressor 
Cervical cancer  Notch1-2, Jagged1-2, DLL4 oncogenes; Notch1 
tumour suppressor 
Cholangiocarcinoma  Notch1; 35% FBXW7 mutations 
Colorectal cancer  Notch1-2, Jagged1-2, DLL4; 8%-9% FBXW7 
mutations 
Cutaneous squamous cell 
carcinoma 
 60-70% Notch1 and >25% Notch2 mutations 
Glioblastoma multiforme  Notch1-2, Jagged1, DLL1 oncogenes; Notch1 
tumour suppressor 
Head and neck squamous cell 
carcinoma 
 15-20% Notch1 mutations; Notch1 can be an 
oncogene and a tumour suppressor 
Hepatocellular carcinoma  Notch1-2 
Lung squamous cell 
carcinoma 
 5-10% Notch1 mutations; Notch2  
Medulloblastoma   Notch1 tumour suppressor; Notch2 oncogene 
Melanoma  ~50% Notch1 overexpression 
Non-small cell lung cancer  10%Notch1 mutations; Notch3; Jagged2 
Ovarian cancer  Undetermined  
Pancreatic cancer  Jagged2 (90%) and DLL4 (50%) 
overexpression; Notch2, Notch4 oncogene; 
Notch1 tumour suppressor 
Prostate cancer  Notch1 tumour repressor, Jagged1 oncogene 
Renal cell carcinoma  Undetermined  
Small cell lung cancer  Notch1, Notch2 




























several stages of normal early T-cell development51. The majority of these mutations consist of 
single amino acid substitutions, insertions, and deletions. The HD domain mutations induce ligand 
independent signalling, while C-terminal mutations lead to the partial or complete deletion of the 
PEST domain and increase the half-life of the NICD11, 51. Less than 1% of all T-ALL cases show a 
t(7;9) chromosomal translocation that results in a truncated form of the Notch1 protein through the 
translation of a series of truncated mRNAs. These truncated alleles lack the NRR region of the 
receptor and have been associated with ligand-independent activation16, 51, 94. 
Breast cancer  
Notch plays a crucial role in mammary development and, as a result, abnormalities in the pathway 
lead to mammary tumourigenesis. The first indication of a link between Notch and breast cancer 
came with the finding that the Notch4 locus is the integration site for the mouse mammary tumour 
virus95. Since then Notch has been shown to exert its oncogenic effects in breast cancer through 
cooperation with a number of growth promoting proteins and pathways including Ras71, enhanced 
cyclin A and B expression, activation of Akt signalling with an associated reduction in apoptosis, 
and inhibition of p53 and Foxo3a69, 96-98. Notch also induces expression of the transcriptional 
repressor, Slug, and concomitantly promotes epithelial-to-mesenchymal transition (EMT) in E-
cadherin-negative breast cancer cells99. Furthermore, the aberrant activation of Notch signalling 
through the RBP-Jk pathway has been linked to human breast cancer as it leads to the accumulation 
of the NICD which is able to transform normal breast epithelial cells into cancerous cells100. 
Finally, loss of Numb has been identified in more than 50% of human mammary carcinomas 
leading to enhanced Notch signalling101. 
In terms of specific receptor and ligand species, the over-expression of Notch1, 3, 4 and Jagged1 
has been linked to poor overall survival in breast cancer patients96, 98, 101-104 while Notch2 has been 
shown to induce apoptosis and have a tumour suppressive role in breast cancer lines105. Notch3 
plays an important role in the proliferation of ErbB2-negative breast tumour cells106 whilst tumours 
expressing high levels of Notch4 appear highly vascularised and aggressive105.  
Melanoma  
Melanomas are highly aggressive neoplasms that are unresponsive to most common therapies. The 
Notch pathway is important for the survival of immature melanocytes through the inhibition of 
apoptosis107. Notch1 has been shown to enhance primary melanoma cell growth whilst having little 
effect on metastatic cells108. The authors also showed that Notch expression was mediated by β-
catenin and its functional inhibition reversed the effects of Notch on tumour growth and metastasis. 
The promotion of primary melanoma progression by Notch1 is also thought to occur through the 
activation of the MAPK/PI3-kinase/Akt pathways and the upregulation of N-cadherin expression109. 
Dysregulated Notch1 also promotes melanomagenesis under hypoxic conditions through its 
interaction with PI3/Akt and NF-κB signalling. Low oxygen is able to upregulate Notch1 signalling 
via stabilisation of HIF-1α (hypoxia-inducible factor-1)68. 
 
Notch signalling in a tumour suppressor role 
Skin carcinomas  
In contrast to its oncogenic role in melanoma progression, Notch1 has been identified as a tumour 
suppressor in mouse basal cell and squamous cell carcinomas of the skin where it interacts with the 
Wnt and Hedgehog pathways108, 110. In keratinocytes, Notch signalling is able to promote 
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differentiation and suppress tumourigenesis. Activated Notch1 leads to keratinocyte growth arrest 
by increasing p21WAF1/Cip1 expression (cyclin/CDK inhibitor) through RBP-jK-dependent 
transcription111. p21 also acts as a negative transcriptional regulator of Wnt expression downstream 
of Notch1112. Notch1 can also suppress the expression of p63 (a modulator of Notch1-dependent 
transcription) in both human and murine keratinocytes113. Deletion of Notch1 results in epidermal 
and corneal hyperplasia111 while Notch1 deficiency is associated with the upregulation of Gli2 
which leads to the development of basal-cell tumours114. 
Small cell lung carcinoma 
Small cell lung carcinoma (SCLC) is a neuroendocrine subtype of lung cancer with a high mortality 
rate. Notch signalling has a tumour suppressive role in SCLC as indicated by the loss-of-function 
mutations in human tumours. The Notch family of receptors is affected by genomic alterations in 
25% of SCLC cases115. The majority of the identified mutations are heterozygous and mainly 
cluster in the EGF-like repeat region of Notch1. Most aberrations are frameshift and nonsense 
mutations as well as substitutions116.  Notch signalling is able to cause growth arrest associated with 
G1 cell cycle block and upregulate the expression of p21
waf/cip1 and p27kip1 in SCLC cancer cell lines 
with cycle arrest being linked to the repression of hASH1 and induction of the MAPK/Ras 
pathway117. 
 
Notch signalling and tumour angiogenesis 
Tumour growth and metastasis is dependent on angiogenesis which is controlled by multiple 
signalling mechanisms such as the VEGF, FGF and hepatocyte growth factor (HGF) pathways. The 
Notch signalling pathway plays a pivotal role in vascular development and tumour angiogenesis, 
from vessel maturation, branching and cell differentiation to cell proliferation, survival and 
apoptosis78, 118. The VEGF and Notch pathways have independent but complementary functions in 
tumour angiogenesis; VEGF can stimulate the expression of Notch receptors and ligands while 
Notch is able to regulate the expression of VEGFs79, 118, 119. DLL4 haploinsufficiency leads to 
severe vascular defects in embryos and increased expression of the ligand is associated with human 
cancers120, 121. Many studies have reported that DLL4 acts as a negative regulator of tumour 
angiogenesis by disrupting vessel density and structure122-124. Some data, however, suggest that 
inhibition of the DLL4/Notch pathway induces vascular neoplasms79, 119, 125. 
 
Notch signalling and cancer stem cells 
Stem cells are characterised by their capacity for self-renewal and increasing data point toward the 
existence of cancer stem cells (CSCs). These ‘tumour-initiating cells’ are self-sustaining and 
capable of indefinite self-replication all the while showing resistance to chemotherapy and radiation 
which means that their complete eradication is necessary to obtain a cure for cancer. The Notch 
pathway, along with Wnt and Hedgehog, is essential for the maintenance of this population of cells 
and contributes to inflammatory signalling which promotes the stem-like cell phenotype98, 126. 
Recent work has shown that Notch plays a central role in breast and glioma CSCs. Notch1-
transformed mouse mammary tumors have been shown to harbour a rare mammary tumor-initiating 
cell population and the receptor contributes to mammary tumour-initiating activity127. The authors 
demonstrated that Notch1 over-expression was able to increase the rate of tumoursphere formation 
in murine mammary tumour cell cultures through expression of the embryonic stem cell 
transcription factor, Nanog. Notch4 signalling has also been shown to be enhanced 8-fold in breast 
CSCs103. In glioblastoma models, knockdown of Notch ligands through RNA interference was 




Strategies to regulate Notch signalling for cancer therapy 
The range of roles exhibited by Notch signalling in tumourigenesis, angiogenesis and CSC 
maintenance makes it a viable therapeutic target for cancer. Inhibition of the Notch pathway with 
various agents from small molecule inhibitors to large molecule antibodies is being actively 
investigated as there is a need to identify new, less toxic and more efficacious disease treatments. 
Notch-related antibodies 
Molecules that target Notch receptors or ligands in a specific manner should, theoretically, reduce 
the therapeutic complications that arise from using non-selective compounds in cancer treatment. 
An attractive prospect in this respect is that of monoclonal antibody (mAb) therapy. However, 
monoclonal antibodies cannot cross the blood-brain barrier so they cannot, unmodified, be used 
against primary brain tumours and metastases and have a short half-life. 
Using phage display technology, mAbs that can recognise specific ligands and receptors have been 
generated50. These antibodies can act as potent inhibitors of the Notch pathway by preventing 
ligand-receptor interaction or proteolytic cleavage, thus inhibiting the production of the NICD96, 129. 
Aste-Amezaga et al. 129 generated two types of mAb against Notch1; one of which recognized the 
NRR of the receptor and the other of which interacted with the ligand binding domain. Both 
antibodies were able to downregulate Notch signalling with the NRR-specific antibody having anti-
angiogenic effects on tumours. However, the same authors noted that dual Notch1 and Notch2 
mAb-mediated inhibition caused gastrointestinal toxicity. Antibodies that bind to overlapping 
epitopes in the NRR region of Notch3 have been shown to inhibit the pathway by stabilising the 
auto-inhibited state and preventing proteolysis21 whilst the antibody, OMP-59R5 (tarextumab), 
which is a Notch2/Notch3 antagonist, has shown promising results in various cancer models, both 
as a single agent or in combination with other drugs130. 
Antibodies against Notch ligands are also under development. An anti-DLL4 antibody124 and a 
soluble Dll4-Fc fusion protein123, 131 have been shown to have anti-tumour activity that disrupts 
angiogenesis and inhibits tumour growth. OMP-21M18 is an antibody against DLL4 that blocks 
ligand interaction with Notch1 and Notch4 thus inhibiting the signalling pathway. Multiple early-
stage clinical trials are being conducted to test the efficacy of OMP-21M18 as a single agent or in 
combination with chemotherapy13, 132, 133 
Finally, A5226A, an antibody against the extracellular domain of nicastrin (a component of the -
secretase complex), is able to neutralise the activity of γ-secretase without causing any off-target 
effects134. 
Notch signalling decoys 
Soluble decoys of the extracellular domain of Notch receptors and ligands appear to inhibit 
signalling. Funahashi et al.121 employed a construct containing the 36 EGF repeats of rat Notch1 
fused to human Fc and demonstrated that it blocked Notch signalling in endothelial cells and 
impaired tumour neoangiogenesis with a 58% decrease in microvessel density in xenograft models. 
Monomeric and dimeric forms of DLL-1 generated by fusing the extracellular domain to either a 
series of myc epitopes or to the Fc portion of human IgG-1 have also been shown to impair the 
activation of Notch by tethered DLL-1, suggesting a direct competition between soluble and 
tethered ligands59. Similarly, soluble Jagged1 has been shown to repress the function of its 
transmembrane counterpart135. Although not strictly a decoy, the soluble protein, epidermal growth 
factor-like domain 7 (EGFL7), has been shown to suppress endothelial cell proliferation, sprouting 
and migration in a manner reminiscent of Notch inhibition136. Furthermore, the authors 
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demonstrated a physical interaction between Notch and EGFL7 suggesting that the latter protein 
might compete with Notch-ligand binding to inhibit angiogenesis. 
γ-secretase inhibitors 
Proteolytic cleavage of Notch receptors and/or ligands by the γ-secretase complex is a prerequisite 
for the downstream transcriptional changes associated with Notch signalling. -secretase inhibitors 
(GSIs), therefore, inhibit Notch signalling by reducing the formation of the NICD. These 
compounds have cytostatic and cytotoxic activities in various cancer cells. However, the drawback 
of these effects is that most GSIs are not highly specific as they impair the proteolysis of a range of 
secretase substrates including DLLs, Jagged, CD44, E-cadherin, amyloid precursor protein and 
N-cadherin. Two classes of GSIs have been developed with differing specificities; non-transition 
state inhibitors and competitive inhibitors of the presenilin catalytic site133. 
RO4929097 is a competitive oral GSI that shows anti-tumour activity in multiple xenograft models. 
The inhibitor does not block proliferation or induce apoptosis but instead it produces a less 
transformed phenotype137, 138. The compound can impair angiogenesis but its effects in this respect 
are limited by high tumour levels of IL6 and IL8139. RO4929097 has been shown to downregulate 
the expression of Notch target genes in breast cancer cell lines126 and to reduce the tumour initiating 
potential of melanoma cells140, 141. In addition, it has also been shown to reduce the expression of 
Notch target genes (Hes1, 3 and 5) in a dose-dependent manner in glioma tumour-initiating cells142. 
However, it was later shown that RO4929097 had limited anti-tumour activity in established glial 
tumours but that its efficacy was enhanced when used in combination with various other established 
chemotherapeutic agents143. Similarly, a phase 1 study of patients with a range of refractory solid 
tumours (predominantly colon) demonstrated a clinical benefit in colon and cervical cancer patients 
when RO4929097 was used in combination with capecitabine144. The former compound seemed to 
enhance the sensitivity of tumour cells to capecitabine. However, common side effects included 
grade 3 and 4 toxicities in relation to nausea, vomiting, diarrhoea, fatigue and hypophosphatemia. 
PF-03084014 is a non-competitive and selective GSI that has been shown to reduce endogenous 
NICD levels and downregulate the Notch target genes Hes-1 and cMyc in the T-ALL cell line HPB-
ALL145. The authors demonstrated growth inhibition of several T-ALL cell lines via cell cycle 
arrest and the induction of apoptosis. Furthermore, the inhibitor reduced cell proliferation and 
induced apoptosis in HPB-ALL tumours. Used in combination with fludarabine, PF-03084014 
induced selective apoptosis in Notch1-mutated chronic lymphocytic leukaemia cells and 
upregulation of HRK, a proapoptotic gene146. Furthermore, the inhibitor has been shown to exhibit 
synergistic activity with dexamethasone (a glucocorticoid) in human T-ALL cell lines and primary 
human T-ALL patient samples147. The authors also demonstrated that the combination of 
compounds was highly efficacious in reducing the tumour burden in a xenograft model of T-ALL 
and that dexamethasone ablated the gastrointestinal toxicity of PF-03084014. Similarly, synergistic 
activity of PF-03084014 with docetaxel has been shown in triple-negative breast cancer models. 
The combination of the two drugs reversed the endothelial mesenchymal transition phenotype, 
induced apoptosis in bulk tumours and eliminated cancer stem cells148 
DAPT (N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester / GSI-IX) is a GSI 
that has been widely used to evaluate the role of Notch signalling in various cell types such as 
muscle stem cells, neural stem cells, ovarian cancer cells and tongue carcinoma cells80, 149, 150. 
DAPT blocks cellular proliferation and induces apoptosis through expression of p21 and regulation 
of cyclin A in Ishikawa endometrial cancer cells151 and reduces proliferation in adipose derived 
stem cells via regulation of Notch and Runx2 expression150. DAPT can also inhibit Notch1 in 
gastric cancer cells which in turn leads to EMT inhibition152. Synergistic anti-leukaemic activity 
was observed following the pretreatment of ovarian cell lines resistant to cisplatin with DAPT153. 
Furthermore, the authors demonstrated that the drug combination inhibited tumour growth and 
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induced G2 cell cycle arrest and apoptosis through modulation of cyclin B1, Bcl-2 and caspase-3. 
DAPT showed no effect on tumour angiogenesis in colon adenocarcinoma in obese mice154 but it 
was able to interfere with VEGF signalling in glioblastomas by decreasing VEGFR1 expression 
which led to uncoupling of tumour vessel density from vessel function80. However, the authors also 
showed that DAPT increased VEGFR2 expression and enhanced endothelial cell proliferation in 
combination with VEGF treatment. 
MRK-003 is a potent GSI that exhibits good preclinical activity in several T-ALL and breast cancer 
cell lines. Intermittent treatment (3 days per week) is sufficient to induce Notch1-mediated cell 
cycle arrest and apoptosis in T-ALL155. Combining MRK-003 with trastuzumab (Herceptin) 
prevents ErbB-2 positive breast tumour recurrence while a combination of MRK-003 with lapatinib 
significantly reduces tumour growth156. MRK-003 treatment promotes caspase-dependent apoptosis 
and blocks proliferation in non-Hodgkin’s lymphoma and multiple myeloma cell lines by 
decreasing the levels of NICD, Hes1 and cMyc157. Moreover, the authors demonstrated that the 
inhibitor upregulated pAkt expression while downregulating the levels of p21, Bcl-2 and Bcl-XI in 
multiple myeloma cells and cyclin D1, Xiap and Bcl-XI in non-Hodgkin's lymphoma cells. MRK-
003 has also been shown to cause cytotoxicity and growth inhibition in a mouse model of pancreatic 
ductal adenocarcinoma158 but appears to reduce oxaliplatin-induced apoptosis in human colon 
cancer cells by increasing the levels of the anti-apoptotic proteins Mc1-1 and Bcl-xL159. 
Compound E is a selective, non-competitive GSI that has shown anti-tumour activity in several pre-
clinical studies. The treatment of T-ALL cell lines with Compound E for 5-7 days has been shown 
to reversibly inhibit cell proliferation, cause cell cycle block and differentiation (the latter only in 
some of the cell lines studied)160. Treatment of 14 days or longer was required to induce significant 
apoptosis but the authors also found that Compound E sensitized cells to the effects of 
dexamethasone raising the potential for the use of the drug combination to obtain efficient 
therapeutic effects in T-ALL. Another study tested the response of compound E in four T-ALL cell 
lines in combination with several chemotherapeutic drugs. GSI treatment showed inconsistencies: it 
led to downregulation of Notch in one line, had no effect on another and induced chemotherapy 
resistance in two of the cell lines tested91. 
GSI-I can induce cell cycle arrest and apoptosis in breast cancer cells with estrogen receptor (ER)-
negative cell lines showing increased sensitivity26. Treatment of precursor-B acute lymphoblastic 
leukaemia (ALL) blasts with GSI-I induced apoptosis and caused nuclear accumulation of cleaved 
Notch1 and Notch2 concomitant with an inhibition of the Notch targets Hey2 and Myc161 
MK-0752 is a novel GSI that has shown promising early results. The drug has been shown to 
reduce breast cancer stem cell numbers in tumourgrafts and to enhance the efficacy of docetaxel in 
pre-clinical studies162. In a 20-patient pilot study, MK-0752 was tested against early stage ER+ 
breast cancer and showed significant biomarker response in all tumours through modulation of 
Notch activity163. In another study investigating the effect of MK-0752 on advanced solid tumours, 
the inhibitor significantly impaired Notch signalling and a limited proportion of patients showed 
disease stabilization for longer than 4 months (one showed a complete response)164. 
Although GSIs show promising results in clinical studies, they fail to distinguish between 
individual Notch receptors and they inhibit other signalling pathways that utilise the γ-secretase 
complex. This lack of specificity can lead to gastrointestinal toxicity due to the rapid differentiation 
of progenitor cells into secretory goblet cells in the intestinal crypts (goblet cell metaplasia) being 
impaired by Notch inhibition. Other GSI-associated adverse effects include skin disorders such as 
erythema, rash and pruritus or headaches 96, 133, 165. However, as mentioned earlier, some studies 
have demonstrated that the combination of GSIs with other drugs such as glucocorticoids might 




Agents that interfere with the Notch signalling transcriptional activator complex have also been 
generated. SAHM1 is a permeable peptide that directly antagonises the assembly of the ternary 
complex and causes potent suppression of Notch target genes. SAHM1 blocks MAML1 recruitment 
and forms a transcriptionally inert complex with Notch and CSL. This inhibits Notch signalling and 
blocks tumour growth without showing gastrointestinal side effects166. TR4 is another dominant 
negative peptide derived from MAML1 that has shown promising results in human mammary and 
colon xenograft models. Moreover, the compound is able to cross the blood-brain barrier so it can 
potentially be used against brain tumours167. 
 
Concluding remarks 
A plethora of studies have demonstrated how aberrant Notch signalling increases cellular 
proliferation, induces epithelial-to-mesenchymal transition, maintains the cancer stem cell pool and 
inhibits apoptosis. The multifaceted role of Notch in cancer development/progression makes it an 
attractive therapeutic target and its cross-talk with other signalling pathways opens the door for the 
use of combinational therapeutic strategies. However, the efficacy of any Notch-targeted treatments 
must be considered in the light of drug specificity and related off-target toxicities. Furthermore, the 
role Notch signalling in cancer, as in differentiation, is context dependent; it can promote 
oncogenesis in some tissues and prevent neoplastic transformation in others. Nonetheless, the use of 




ADAM, a disintegrin and metalloproteinase; CADASIL, cerebral autosomal dominant arteriopathy 
with subcortical infarcts and leukoencephalopathy; CSC, cancer stem cell; CSL, CBF1 Suppressor 
of Hairless, Lag-1; DAPT, N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester; 
DLL, Delta-like ligand; DSL, Delta/Serrate/Lag2; EGF, epidermal growth factor; EGFL7, 
epidermal factor-like domain 7; EGFR, epidermal growth factor receptor; EMT, epithelial-to-
mesenchymal transition; ER, estrogen receptor; FGF, fibroblast growth factor; FGFR, fibroblast 
growth factor receptor; GSI, -secretase inhibitor; HD, heterodimerisation domain; HGF, 
hepatocyte growth factor; HIF-1α, hypoxia-inducible factor-1; LNR, LIN-12-Notch repeat; mAb, 
monoclonal antibody; MAML, Mastermind-like; MAPK, Ras/Mitogen Activated Protein Kinase; 
NICD, Notch intracellular domain; NRR, negative regulatory region; PEST, proline, serine, 
glutamic acid and threonine-rich; RAM, RBP-Jκ/CBF1 association module; SCLC, small cell lung 
carcinoma; T-ALL, T-cell acute lymphoblastic leukaemia; TAD, transactivation domain; TACE, 
tumour necrosis factor alpha-converting enzyme; TGF-β, transforming growth factor-β; TNF, 
tumour necrosis factor alpha; VEGF, vascular endothelial growth factor; VEGFR, vascular 
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